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Serum	creatinine	and	urine	protein	:	creatinine	ratio	in	dogs	affected	by	
myxomatous	mitral	valve	disease.	
Cardiac	disease	 is	often	associated	with	worsening	renal	 function,	 in	humans.	The	cardiorenal	syndromes	
(CRS)	 were	 defined	 as	 disorders	 of	 the	 heart	 and	 kidneys	 whereby	 acute	 or	 chronic	 dysfunction	 in	 one	
organ	 may	 induce	 acute	 or	 chronic	 dysfunction	 of	 the	 other.	 Five	 subtypes	 of	 the	 syndromes	 were	
identified;	 of	 these,	 CRS	 2	 indicates	 chronic	 abnormalities	 in	 cardiac	 function	 causing	 progressive	 and	
potentially	 permanent	 chronic	 kidney	 disease.	 Recent	 investigations	 support	 the	 role	 of	 central	 venous	
congestion,	neurohormonal	activation,	anemia,	oxidative	stress	and	renal	sympathetic	activity	as	potential	
contributors	to	this	complex	syndrome.	The	main	marker	of	kidney’s	disease	in	humans	is	considered	the	
glomerular	 filtration	 rate.	 However,	 serum	 creatinine	 (sCr)	 and	 urine	 protein:creatinine	 ratio	 (UPC)	 are	
recognized	as	predictors	of	worsening	renal	function	as	well.	The	aim	of	this	study	was	to	investigate	renal	
function	in	dogs	with	myxomatous	mitral	valve	disease	(MMVD)	and	cardiac	remodeling	(ACVIM	stage	≥B2)	
by	 measurement	 of	 sCr	 and	 UPC.	 This	 is	 an	 observational	 case-control	 study.	 Twenty	 dogs	 of	 various	
breeds,	 aged	 7-15	 years,	 affected	 by	 MMVD	 with	 hemodynamically	 signiﬁcant	 mitral	 regurgitation	 and	
cardiac	remodeling	(left	ventricle	internal	diameter	in	diastole	normalized	according	to	allometric	scaling	≥	
1.7	and/or	LA/Ao	ratio	≥	1.6)	were	included	in	the	study.	Twenty	healthy	dogs	of	various	breeds,	aged	7-15	
years	were	included	as	controls.	Dogs	with	congenital	or	acquired	cardiac	disease	other	than	MMVD,	dogs	
with	 previous	 history	 or	 clinical	 signs	 at	 presentation	 of	 systemic,	 inflammatory	 or	 infectious	 disease,	
malignancies,	hypertension	(systolic	blood	pressure	>160mmHg)	or	evidence	of	other	organ	dysfunction	or	
hyperthermia	were	not	 included	 in	the	study.	On	each	dog	physical	examination,	echocardiography,	ECG,	
RX,	systemic	blood	pressure	measurement,	blood	and	urine	analysis	were	performed	in	order	to	obtain	a	
classification	of	MMVD	(ACVIM	consensus	statement	2009)	and	chronic	kidney	disease	(IRIS	classification).	
Both	 dogs	 with	MMDV	 and	 controls	 resulted	 IRIS	 class	 1.	 The	 study	 revealed	 no	 statistically	 significant	
difference	in	sCr	and	UPC	between	dogs	with	MMVD	(sCr:	0.76	mg/dl,	0.41	–	1.21;	UPC:	0.26,	0.00	–	1.03)	
(mean;	 range)	 and	 controls	 (sCr:	 0.74	mg/dl,	 0.37	 –	 1.21;	 UPC:	 0.21,	 0.03	 –	 0.98)	 (mean;	 range).	 These	
results	suggest	that	hemodynamically	signiﬁcant	mitral	regurgitation	with	cardiac	remodeling	and	expected	
neurohormonal	system	activation	do	not	affect	proteinuria	and	renal	function.	Nevertheless	further	studies	
are	needed	to	confirm	these	findings.			
	
	
